永安药业
(002365)
| 流通市值：30.21亿 | | | 总市值：36.25亿 |
| 流通股本：2.46亿 | | | 总股本：2.95亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 948,703,343.51 | 563,704,504.5 | 235,897,297 | 783,167,007.89 |
| 营业收入 | 948,703,343.51 | 563,704,504.5 | 235,897,297 | 783,167,007.89 |
| 二、营业总成本 | 804,993,472.61 | 505,141,633.94 | 226,434,212.68 | 791,244,833.8 |
| 营业成本 | 671,680,321.84 | 420,951,623.55 | 188,175,215.05 | 650,684,052.19 |
| 税金及附加 | 10,230,315.7 | 6,273,571.48 | 3,083,096.09 | 10,030,751.49 |
| 销售费用 | 23,809,373.03 | 17,139,491.76 | 9,228,146.66 | 40,065,902.58 |
| 管理费用 | 52,182,062.95 | 33,838,146.23 | 14,407,352.39 | 59,700,447.16 |
| 研发费用 | 37,104,676.41 | 20,815,527.35 | 8,622,162.46 | 30,876,613.76 |
| 财务费用 | 9,986,722.68 | 6,123,273.57 | 2,918,240.03 | -112,933.38 |
| 其中:利息费用 | 222,271.73 | 31,272.76 | 10,397.51 | 941,505.85 |
| 其中:利息收入 | 301,522.63 | 226,156.48 | 124,134.13 | 1,357,016.04 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -8,260,016.17 | -3,416,124.22 | -3,507,210.49 | -1,085,650.93 |
| 加:投资收益 | 15,892,565.92 | 9,315,453.45 | 5,242,302.15 | 30,560,208.94 |
| 资产处置收益 | -98,159.47 | 8,229.04 | -33,352.93 | 185,682.47 |
| 资产减值损失(新) | -3,242.04 | -3,242.04 | -3,242.04 | -16,527,392.86 |
| 信用减值损失(新) | -10,243,017.42 | -7,056,308.75 | -1,654,458.36 | 124,223.68 |
| 其他收益 | 1,731,747.95 | 1,237,938.43 | 647,764.19 | 5,470,623.02 |
| 四、营业利润 | 142,729,749.67 | 58,648,816.47 | 10,154,886.84 | 10,649,868.41 |
| 加:营业外收入 | 363,037.04 | 324,515.58 | 18,716.03 | 307,044.1 |
| 减:营业外支出 | 2,648,343.15 | 1,030,546.15 | 1,014,713.61 | 1,079,022.86 |
| 五、利润总额 | 140,444,443.56 | 57,942,785.9 | 9,158,889.26 | 9,877,889.65 |
| 减:所得税费用 | 26,946,326.3 | 15,157,843.71 | 1,170,176.54 | 2,687,825.14 |
| 六、净利润 | 113,498,117.26 | 42,784,942.19 | 7,988,712.72 | 7,190,064.51 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 113,498,117.26 | 42,784,942.19 | 7,988,712.72 | 7,190,064.51 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 114,429,446.05 | 43,408,294.2 | 7,736,703.46 | 22,493,429.92 |
| 少数股东损益 | -931,328.79 | -623,352.01 | 252,009.26 | -15,303,365.41 |
| 扣除非经常损益后的净利润 | 109,378,100.48 | 39,361,558.1 | 7,250,939.13 | -2,441,923.78 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.4 | 0.15 | 0.03 | 0.08 |
| (二)稀释每股收益 | 0.4 | 0.15 | 0.03 | 0.08 |
| 八、其他综合收益 | -307,439.09 | -232,563.76 | -114,894.12 | -170,283.48 |
| 归属于母公司股东的其他综合收益 | -307,439.09 | -232,563.76 | -114,894.12 | -170,283.48 |
| 九、综合收益总额 | 113,190,678.17 | 42,552,378.43 | 7,873,818.6 | 7,019,781.03 |
| 归属于母公司股东的综合收益总额 | 114,122,006.96 | 43,175,730.44 | 7,621,809.34 | 22,323,146.44 |
| 归属于少数股东的综合收益总额 | -931,328.79 | -623,352.01 | 252,009.26 | -15,303,365.41 |
| 公告日期 | 2026-10-30 | 2026-08-28 | 2026-04-30 | 2026-04-17 |
| 审计意见(境内) | | | | 标准无保留意见 |